This week, GVK Biosciences said that the US Food and Drug Administration has licensed GOSTAR, a manually curated database of structure-activity relationship, pharmacokinetic, and toxicity data.
GOSTAR contains over 6.5 million manually curated compounds from over 2.5 million patents and 400,000 journals; and more than 18 million quantitative SAR points. It also includes a proprietary drug repurposing platform that pulls in data from other GVK Bio proprietary databases.
GVK Bio said that it will collaborate with the FDA on drug repositioning projects, the first of which will identify alternative therapeutic indications for compounds used to treat neglected and orphan diseases.
The firm will also work with the FDA to enhance GOSTAR's "repositioning and repurposing workflow, and make it available to the entire research community," according to Sreeni Devidas, GVK Bio's vice president of business development.
The financial details of the agreement were not disclosed.